Samsung Biologics has entered into a strategic partnership for the long-term commercial manufacturing of Pfizer’s multi-product biosimilars portfolio.
Under the new deal, valued at $411 Million, Samsung Biologics will provide Pfizer with additional capacity for large-scale manufacturing for a multi-product biosimilars portfolio.
This partnership is a significant step forward for both companies in the rapidly growing biosimilars market.
- Samsung Biologics will provide additional capacity for large-scale manufacturing
- The partnership is for the long-term commercial manufacturing of Pfizer’s multi-product biosimilars portfolio
- The deal is a significant step forward for both companies in the rapidly growing biosimilars market
